Guideline | Drug Name |
---|---|
Turalio (pexidartinib) | Turalio (pexidartinib) |
Tykerb (lapatinib) | Tykerb (lapatinib) |
Tysabri (natalizumab) | Tysabri (natalizumab) |
Ultomiris (ravulizumab-cwvz) | Ultomiris (ravulizumab-cwvz) |
Unituxin (dinutuximab) | Unituxin (dinutuximab) |
Urea Cycle Disorder Agents - PA, NF | Buphenyl (sodium phenylbutyrate), Olpruva (sodium phenylbutyrate), Pheburane (sodium phenylbutyrate), Ravicti (glycerol phenylbutyrate) |
Ustekinumab - PA, NF | Stelara IV (ustekinumab), Ustekinumab IV, Imuldosa IV (ustekinumab-srlf), Otulfi IV (ustekinumab-aauz), Pyzchiva IV (ustekinumab-ttwe), Selarsdi IV (ustekinumab-aekn), Steqeyma IV (ustekinumab-stba), Wezlana IV (ustekinumab-auub), Yesintek IV (ustekinumab-kfce), Stelara SC (ustekinumab), Ustekinumab SC, Imuldosa SC (ustekinumab-srlf), Otulfi SC (ustekinumab-aauz), Pyzchiva SC (ustekinumab-ttwe), Selarsdi SC (ustekinumab-aekn), Steqeyma SC (ustekinumab-stba), Wezlana SC (ustekinumab-auub), Yesintek SC (ustekinumab-kfce) |
Venclexta (venetoclax) | Venclexta (venetoclax) |
Veopoz (pozelimab-bbfg) | Veopoz (pozelimab-bbfg) |
Verzenio (abemaciclib) | Verzenio (abemaciclib) |
Vimizim (elosulfase alfa) | Vimizim (elosulfase alfa) |
Voranigo (Vorasidenib) | Voranigo (Vorasidenib) |
Votrient (pazopanib) | Votrient (pazopanib) |
Vyndaqel (tafamidis meglumine), Vyndamax (tafamidis) | Vyndaqel (tafamidis meglumine), Vyndamax (tafamidis) |
Vyxeos (daunorubicin and cytarabine) | Vyxeos (daunorubicin and cytarabine) |
Wegovy cardiovascular risk reduction-EHB | Wegovy (semaglutide) |
Xalkori (crizotinib) - PA, NF | Xalkori (crizotinib) |
Xdemvy (lotilaner) PA, NF | Xdemvy (lotilaner ophthalmic solution) |
Xeljanz, Xeljanz XR (tofacitinib) | Xeljanz (tofacitinib) tablets and oral solution, Xeljanz (tofacitinib) tablets, Xeljanz XR (tofacitinib) extended-release tablets |
Xenazine (tetrabenazine) | Xenazine (tetrabenazine) |